← 返回中文导览OiOi 医疗学习 · OnCo 肿瘤知识探索原项目 OnCo ↗

Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Probiotics for Abemaciclib-Induced Abdominal Discomfort.

Probiotics for Abemaciclib-Induced Abdominal Discomfort.

A phase 2 trial of an investigational treatment in advanced solid tumours, run by Leeuwenhoek Laboratories Co. Ltd., now recruiting.

Recruiting

Overview Taking part Connected3

Overview

Probiotics for Abemaciclib-Induced Abdominal Discomfort. is a phase 2 interventional study registered as NCT07605728 by Leeuwenhoek Laboratories Co. Ltd., with 80 participants planned, started 2026-05-15 and due to reach its primary completion in 2029-06-30.

Setting

A Randomized, Phase II Study About Probiotics to Alleviate Abemaciclib-induced Abdominal Discomfort Under Standard Anti-diarrhea Drug Loperamide and Changes of Metabolic Factors in Blood.

Phase

Phase 2

Sponsor

Leeuwenhoek Laboratories Co. Ltd.

Registry

Started

2026-05-15 (estimated)

Enrolled

80 enrolled

Taking part

NCT07605728recruiting

Run by: Leeuwenhoek Laboratories Co. Ltd.
Open to: 18 Years and over, any sex
Enrolment: 80 (estimated)
Sites: 1, 1 recruiting
Countries: Taiwan
Registry updated: 2026-05-26

The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.

ClinicalTrials.gov data courtesy of the US National Library of Medicine.

Connected

3

Similar pages

Trial
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Abemaciclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Abemaciclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Shares Abemaciclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Trial
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Trial
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Trial
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.

cancers

Metastatic cancer (cancer that has spread)

technologies

CDK4/6 inhibitors

drugs

ApprovedSmall-molecule CDK4/6 inhibitor

Abemaciclib · Verzenio

Evidence strength30/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
80 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

Make correction

Report a readout

Cancers

Metastatic cancer (cancer that has spread)

Technologies

CDK4/6 inhibitors

Products

Abemaciclib

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07605728

A source that has moved or gone is reported by the weekly link check. /audit/

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sourced, not expert-reviewed

Machine-readable versions of Probiotics for Abemaciclib-Induced Abdominal Discomfort.

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct07605728/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct07605728.

WebMCP tools registered on this page: onco_search, onco_get_entity.